21 completed, 9 active not recruiting, 2 recruiting, 1 available. 14 Phase 1, 14 Phase 3, 4 Phase 2.
By phase and status
Follow retatrutide: new trials by email Literature Review of retatrutide trials Research Report on retatrutide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Effect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight Retatrutide (LY3437943), Placebo, Standardized diet and physical activity counseling throughout the study. - Obesity Phase 2 Recruiting 300 2026-02-15 2026-03-12 A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight Retatrutide - Obesity, Overweight Phase 3 Active not recruiting 600 2026-01-24 2026-06-09 A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight Retatrutide, Placebo - Obesity, Overweight Phase 3 Active not recruiting 250 2025-11-17 2026-04-17 A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) Tirzepatide, Retatrutide, Placebo - Metabolic Dysfunction-Associated Steatotic Liver Disease Phase 3 Recruiting 4500 2025-10-15 2026-10-08 A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia Retatrutide, Placebo - Type 2 Diabetes Mellitus Phase 1 Completed 80 2025-06-06 2026-06-18 A Study to Evaluate the Effect of Retatrutide on Insulin Secretion and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus Retatrutide, Semaglutide, Placebo - Diabetes Mellitus, Insulin Sensitivity Phase 1 Active not recruiting 95 2025-06-02 2026-10-06 A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain Retatrutide, Placebo - Obesity, Overweight Phase 3 Active not recruiting 586 2025-05-29 2026-09-25 A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity Retatrutide, Placebo - Obesity Phase 3 Active not recruiting 643 2025-03-05 2026-03-03 To Investigate the Effect of Retatrutide (LY3437943) on Metoprolol Pharmacokinetics in Healthy Participants Retatrutide, Metoprolol - Healthy Phase 1 Completed 30 2025-02-03 2025-06-05 A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity Retatrutide, Tirzepatide - Obesity Phase 3 Active not recruiting 800 2024-11-01 2026-07-20 The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) Retatrutide, Placebo - Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD) Phase 3 Active not recruiting 10000 2024-04-30 2026-10-08 Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1) Retatrutide, Placebo - Diabetes Type 2 Phase 3 Completed 537 2024-04-10 2026-03-05 A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943 LY3437943, Placebo - Obesity Phase 1 Completed 85 2024-03-20 2025-09-23 Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3) Retatrutide, Placebo - Type 2 Diabetes Phase 3 Active not recruiting 320 2024-03-15 2026-07-20 Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2) Retatrutide, Semaglutide - Diabetes Mellitus, Type 2 Phase 3 Active not recruiting 1250 2024-02-21 2026-09-28 A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese LY3437943, Ethinyl Estradiol, Drospirenone - Overweight Phase 1 Completed 46 2023-09-12 2024-07-26 A Research Study Looking at Similarity Between LY3437943 Versions for Different Injection Devices LY3437943, Test, Reference - Healthy Phase 1 Completed 57 2023-08-29 2024-03-29 A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee Retatrutide, Placebo - Obesity, Overweight Phase 3 Completed 445 2023-08-01 2026-01-21 A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes Retatrutide, Placebo - Overweight or Obesity, CKD Phase 2 Completed 146 2023-07-20 2025-11-25 A Study of LY3437943 in Healthy Participants With a High Body Mass Index LY3437943 - Healthy Phase 1 Completed 85 2023-07-18 2024-10-01
Showing 20 of 33. Sign in to see all of them.
Conditions studied Obesity (17) · Overweight (11) · Diabetes Mellitus, Type 2 (10) · Metabolic Diseases (4) · Endocrine System Diseases (3) · Glucose Metabolism Disorders (3) · Cardiovascular Diseases (2) · Diabetes Mellitus (2) · Kidney Diseases (2) · Renal Insufficiency, Chronic (2) · Sleep Apnea, Obstructive (2) · Weight Loss (2) · Atherosclerosis (1) · Body Weight (1) · Cerebrovascular Disorders (1)
Sponsors Eli Lilly and Company (32) · Hudson Biotech (1)
Countries United States (25) · Canada (10) · Puerto Rico (10) · Argentina (9) · Mexico (9) · United Kingdom (8) · Spain (7) · Australia (6) · Poland (6) · Brazil (5) · India (5) · Germany (4) · Hungary (4) · Romania (4) · Austria (3)
Results publications PMID 41160422 , PMID 42608321 , PMID 36354040 , PMID 37366315 , PMID 37385280 , PMID 38858523 , PMID 40609566 , PMID 41201783 , PMID 42250575 , PMID 42810372 , PMID 42814954
NIH funding 2023 (6) , 2025 (1)